Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort
Luca Gianni(Fondazione IRCCS Istituto Nazionale dei Tumori), W. Eiermann(Olgahospital), Semiglazov Vf(Institute of Oncology NN Petrov), Alexey Manikhas(City Clinical Oncology Center), Aňa Lluch(Hospital Clínico Universitario de Valencia), S. Tjulandin(Russian Cancer Research Center NN Blokhin), Milvia Zambetti(Fondazione IRCCS Istituto Nazionale dei Tumori), Federico Vázquez(Vall d'Hebron Hospital Universitari), Mikhail Byakhow(Central Clinical Hospital No 2 named Semashko), Mikhail Lichinitser(Russian Cancer Research Center NN Blokhin), Miguel Ángel Climent(Fundación Instituto Valenciano de Oncología), Eva Ciruelos, B. Ojeda(Hospital de Sant Pau), Mauro Mansutti(Ospedale Santa Maria della Misericordia di Udine), А. А. Божок(Institute of Oncology NN Petrov), Roberta Baronio(Fondazione Michelangelo), A. Feyereislova(Roche (Switzerland)), Claire Barton(Roche (Switzerland)), Pinuccia Valagussa(Fondazione Michelangelo), José Baselga(Vall d'Hebron Hospital Universitari)
Cited by 1,265
Abstract
Related Papers
No related papers found
Powered by citation graph analysis